Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director compensation and share ownership changes rather than corporate financial performance.
Material Changes
On June 30, 2014, Non-Executive Directors were allocated notional Ordinary Shares and American Depositary Shares (ADSs) for the service period of April 1, 2014, to June 30, 2014. The allocation prices were set at £15.67 per Ordinary Share and $53.64 per ADS. These allocations were communicated to the Company and Directors on July 1, 2014.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share interests in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Non-Executive Directors received notional share allocations on June 30, 2014, for the Q2 2014 service period.
- Allocation prices were £15.67 per Ordinary Share and $53.64 per ADS.
- Specific share counts were allocated to ten Non-Executive Directors, including Sir Christopher Gent (3,988.513 Ordinary Shares) and Professor Sir Roy Anderson (578.334 Ordinary Shares).
- This filing contains no financial performance data or strategic outlook.